Transdermal Drug Delivery System Market Size to Hit USD 10.77 Billion by 2032 – SNS Insider
Technological Advancements and Rising Demand for Non-Invasive Therapies Drives Growth.
Pune, March 04, 2025 (GLOBE NEWSWIRE) — “According to SNS Insider, the global Transdermal Drug Delivery System Market was valued at USD 7.23 billion in 2023, is projected to reach USD 10.77 billion by 2032, growing at a CAGR of 4.54% from 2024 to 2032.”
The transdermal drug delivery system (TDDS) market is seeing high growth rates, thanks largely to the progress in technologies and a heightened inclination towards non-invasive drug delivery methods. Progress in patch technologies and skin penetration technologies has made transdermal systems more effective and easier for patients to follow, presenting a preferred substitute to conventional injectables and oral dosage forms. These advances have broadened the use of TDDS in many areas of medicine, such as pain relief, hormone replacement, and central nervous system (CNS) diseases.
The increasing incidence of chronic diseases requiring long-term therapy has also stimulated the market for effective and patient-compliant methods of drug delivery. Transdermal delivery systems provide sustained and controlled release of drugs, enhancing efficacy and decreasing the frequency of dosing. Moreover, the non-invasive character of TDDS lowers the chances of infection and increases patient compliance, lending itself to extensive use in both homecare and clinical environments.
Get a Sample Report of Transdermal Drug Delivery System Market@ https://www.snsinsider.com/sample-request/5639
Major Players Analysis Listed in this Report are:
- Hisamitsu Pharmaceutical Co., Inc. – Salonpas, MOHRUS TAPE, MOHRUS PAP, MOHRUS PAP XR, Estrana
- Mylan Pharmaceuticals, Inc. – Xulane
- Novartis AG – Exelon Patch
- UCB – Neupro
- GlaxoSmithKline – Nicorette, Nicoderm CQ
- Boehringer Ingelheim GmbH – Butrans Patch
- Johnson & Johnson – Duragesic
- Endo International – Lidoderm
- Purdue Pharma – Butrans, Hysingla ER
- Grünenthal – Transtec
- 3M Company – Transderm Scop
- Noven Pharmaceuticals, Inc. – Vivelle-Dot, Minivelle
- 4P Therapeutics, LLC – 4P-005
Transdermal Drug Delivery System Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.23 billion |
| Market Size by 2032 | US$ 10.77 billion |
| CAGR | CAGR of 4.54% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Key Growth Drivers | Technological advancements, enhanced patient compliance, and increased investment in non-invasive drug delivery solution. |
Segment Analysis
By Technology
In 2023, iontophoresis became the most popular technology in the TDDS industry, holding a market share of 19.1%. It owes its superiority to its potential to deliver the drug in a targeted and controlled manner using a mild electric current, which helps to increase the absorption of drugs without breaking down the skin integrity. The segment of the mechanical array is expected to show exponential growth during the forecast period. Mechanical arrays take advantage of microneedle technology to form microchannels within the skin, allowing effective drug permeation. With their minimally invasive characteristics and ability to deliver a broad spectrum of therapeutic drugs, they are a technology promising to play a significant role in transdermal drug delivery.
By Application
Pain management was the most prominent application area in 2023, by the demand for sustained-release and non-invasive analgesic therapies. Transdermal patches deliver stable plasma drug concentrations, minimizing dosing frequency and improving patient compliance. The hormone therapy application is expected to be the most rapidly growing application in the forecast period. This expansion is fueled by the growing prevalence of hormonal imbalances and the benefits of transdermal delivery in achieving constant hormone levels with reduced systemic side effects.
Need any customization research on Transdermal Drug Delivery System Market, Enquire Now@ https://www.snsinsider.com/enquiry/5639
Transdermal Drug Delivery System Market Segmentation
By Technology
- Electroporation
- Radio Frequency
- Iontophoresis
- Microporation
- Thermal
- Mechanical arrays
- Ultrasound
- Others
By Application
- CNS
- Pain Management
- Cardiovascular
- Hormone
- Immunological
- Metabolic
- Gastrointestinal
- Infection
- Cancer
- Others
Regional Analysis
North America led the TDDS market in 2023, driven by its developed healthcare infrastructure, high incidence of chronic diseases, and strong investment in research and development. The region’s emphasis on novel drug delivery solutions has promoted the uptake of transdermal systems across therapeutic areas.
The Asia-Pacific region is expected to have the highest growth over the forecast period. The reasons for this high growth are rising healthcare spending, expanding awareness of sophisticated drug delivery techniques, and an expanding patient base with chronic diseases. Moreover, partnerships among local and global pharmaceutical firms are likely to increase the availability and uptake of transdermal drug delivery systems in the region.
Recent Developments
- January 2025: Alvogen, Inc. initiated a voluntary nationwide recall of one lot of its Fentanyl Transdermal System 25 mcg/h patches due to a defect in the delivery system. The issue arises from the potential for patches to be multi-stacked and adhered together in a single product pouch. The product is manufactured by Kindeva Drug Delivery L.P. a private-label distributor as an Alvogen.
- January 2024: Novartis revealed encouraging findings from a Phase III trial of their experimental transdermal calcitonin gene-related peptide (CGRP) inhibitor patch for the prevention of migraines. This development highlights the potential of transdermal systems in managing neurological conditions.
Buy a Single-User PDF of Transdermal Drug Delivery System Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/5639
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Prescription and Utilization Trends for Transdermal Drug Delivery (2023), by Region
5.2 Transdermal Drug Delivery Devices Production and Supply Trends (2020-2032)
5.3 Technological Advancements and R&D Investments in Transdermal Systems (2023)
6. Competitive Landscape
7. Transdermal Drug Delivery System Market by Technology
8. Transdermal Drug Delivery System Market by Application
9. Regional Analysis
10. Company Profiles
11. Use Cases and Best Practices
12. Conclusion
Access Complete Report Details of Transdermal Drug Delivery System Market Analysis & Outlook 2024-2032@ https://www.snsinsider.com/reports/transdermal-drug-delivery-system-market-5639
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.